Product Information
CARBAMAZEPINE 200 MG TABLET is a generic product labeled by Major Pharmaceuticals, priced at $0.1194 per EA under NDC 00904617250. Its NADAC has been published 479 times since Aug 2, 2017.
FDA first approved this application on Dec 7, 2005. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
200 mg/1
Manufacturer
Major PharmaceuticalsNDC
00904617250
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CARBAMAZEPINEApproval Type
Generic (ANDA)
FDA Application
ANDA077272FDA Approved
12/7/2005
TE Code
AB
On Market Since
9/20/2010
Pharmacological Classes
Price Statistics
The NADAC for CARBAMAZEPINE 200 MG TABLET has been published 479 times since Aug 2, 2017, and over the history we have for it it has declined 78.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1194 per EA |
|---|---|
| All-time high | $0.5548 (Aug 16, 2017) |
| All-time low | $0.1005 (Jul 17, 2024) |
| 52-week high | $0.1261 |
| 52-week low | $0.1157 |
| Median price | $0.2042 |
| Average price | $0.2403 |
| Largest weekly change | +96.7% (Aug 28, 2024) |
| Weeks tracked | 479 |
| Tracking since | Aug 2, 2017 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Major Pharmaceuticals manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
CARBAMAZEPINE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Mood Stabilizer class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CARBAMAZEPINE 200 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for CARBAMAZEPINE 200 MG TABLET, manufactured by Major Pharmaceuticals, is $0.1194 per EA (NDC 00904617250), effective Sep 30, 2026.
How has the price of CARBAMAZEPINE 200 MG TABLET changed over time?
Over the history we have for it, the NADAC for CARBAMAZEPINE 200 MG TABLET has declined 78.5%. It has been tracked across 479 weekly CMS publications since Aug 2, 2017.
What are the highest and lowest recorded NADAC prices for CARBAMAZEPINE 200 MG TABLET?
Since Aug 2, 2017, the NADAC for CARBAMAZEPINE 200 MG TABLET has ranged from a low of $0.1005 (Jul 17, 2024) to a high of $0.5548 (Aug 16, 2017), with a median of $0.2042 per EA.
Are there cheaper alternatives to CARBAMAZEPINE 200 MG TABLET?
6 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CARBAMAZEPINE 200 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures CARBAMAZEPINE 200 MG TABLET?
CARBAMAZEPINE 200 MG TABLET (NDC 00904617250) is labeled by Major Pharmaceuticals, and CMS classifies it as a generic product.